Introduction {#Sec1}
============

Coronaviruses (CoV) are a family of enveloped, positive-sense, single-stranded RNA viruses that have been described for more than 50 years. Some strains are found to be zoonotic, whereas others may infect humans and transmit from human-to-human (HCoV) \[[@CR1]\]. Multiple strains of Coronavirus are associated with human disease, causing mainly respiratory infections \[[@CR2]\]. Of these, SARS-CoV-1, MERS-CoV, HCoV-OC43, and HCoV-229E are associated with neurological complications \[[@CR3]\]. Large territory stroke, polyneuropathy, myopathy, seizures, and status epilepticus were reported in patients with SARS-CoV-1 outbreak in 2002/2003 \[[@CR4], [@CR5]\]. Intranasal inoculation of the SARS-CoV-1 virus to mice transgenic for the human ACE2 protein led to severe neuronal loss at the brainstem and specifically the respiratory center at the medulla. This was postulated to contribute to the respiratory failure seen in the most severe cases of coronavirus infections, in addition to the primary lung pathology \[[@CR6]\]. The full spectrum of COVID-19 is not fully described yet. Some patients may have no clinical symptoms \[[@CR7], [@CR8]\], while others might suffer from severe disease and even die. The most commonly recognized symptoms are cough, fever, fatigue, shortness of breath, myalgia, anosmia, and sputum production. Other less-reported symptoms include diarrhea, hemoptysis, and nasal congestion \[[@CR7], [@CR9]\]. Growing evidence suggests that SARS-CoV-2 virus has neuroinvasive potential, like other coronaviruses. Hence, it was only a matter of time before neurological complications were reported, especially stroke, neuromuscular disorders, and meningoencephalitis. The goal of this review is to outline the broad spectrum of the neurological consequences of SARS-CoV-2 infection.

Methods {#Sec2}
=======

We conducted a systematic literature search from December 01, 2019 to May 14, 2020 from PubMed and Ovid Medline databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR10]\]. The following search strategy was implemented and these keywords and their synonyms (in the all fields) were combined in each database as follows: ("COVID 19" OR "coronavirus") AND ("brain" OR "CNS" OR "spinal cord" OR "nerve" OR "neurologic" OR "stroke" OR "cerebrovascular" OR "cerebral vein thrombosis" OR "sinus thrombosis" OR "Intracerebral hemorrhage" OR "hemorrhage" OR "myelitis" OR "GBS" OR "Guillain Barre syndrome" OR "neuropathy" OR "radiculopathy" OR "cranial neuropathy" OR "myopathy" OR "myositis" OR "rhabdomyolysis" OR "encephalitis" OR "encephalopathy" OR "meningitis" OR "meningoencephalitis" OR "seizure" OR "convulsion" OR "epilepsy") \[Fig. [1](#Fig1){ref-type="fig"}\]. We included case series and case reports of COVID-19 with evident neurological symptoms or signs. After exclusion of duplicates, all articles were evaluated through title and abstract screening by three independent reviewers (M.G., Q.A., and G.M.). The same three reviewers performed an accurate reading of all full-text articles assessed for eligibility and performed a collection of data to minimize the risk of bias. In case of disagreement among the investigators regarding the inclusion and exclusion criteria, the senior investigator (G.M.) made the final decision. Articles were included if they met the following inclusion criteria: (i) described patients with neurological signs or symptoms attributed to COVID-19 (e.g., focal neurological deficit or impairment of consciousness); (ii) written in English language; and (iii) published in a peer-reviewed journal. The exclusion criteria were: (i) studies conducted in animals or in vitro models or basic science studies; (ii) patients age less than 18 years; and (iii) conference proceedings, pooled analysis, clinical trials, case control studies, case reports, or case series of anosmia or mental health problems in COVID-19, reviews, and books. We assessed the quality of the included studies using the JBI Critical Appraisal Tool, as shown in supplementary Tables 1 and 2.\[[@CR11]\]Fig. 1PRISMA flowchart of the selection of the studies for this review

For each study, the following descriptive, microbiological, and clinical information was extracted: patient demographic data, SARS-CoV-2 testing from nasal swab and CSF, neurological symptoms and signs and their onset in relation to respiratory or gastrointestinal (GI) symptoms or anosmia or dysgeusia, any neurological investigations and CSF or any other relevant laboratory testing (such as CK, LDH, CRP, D-dimer, lupus anticoagulant, fibrinogen, ganglioside antibodies), neurological diagnosis, occurrence of respiratory failure (defined as need for intubation, abnormal PO2 in blood gas, or Glasgow Coma Scale score less than or equal 8), treatments administered for the neurological diagnosis, and final outcome. We studied the following outcomes: good, recovering, poor, and deceased. Good outcome was defined as discharge of the patient to home or a quarantine facility, or the use of the following descriptive terms in the study: "no morbidity", "no worsening" or "discharged well" or "good recovery". Recovering outcome was defined as discharge of the patient to a rehabilitation facility or use of the following descriptive terms: "began to improve", "recovering", or "stayed in the floor". Poor outcome was defined as continuing deterioration of the patient's clinical status, need for ICU admission, continued intubation, or use of the following descriptive terms: "poor" or "no improvement after a certain time of treatment", at the time of submitting the manuscript. Deceased was defined as reported death within 30 days of COVID-19 diagnosis.

Results {#Sec3}
=======

Through the search strategy, we could identify 42 articles about neurological involvement by COVID-19. We were able to identify 82 cases of COVID-19 with neurological complications. The mean age was 62.3 years (22--91). 37.8% of the patients were women (*n* = 31) (Table [1](#Tab1){ref-type="table"}). All but two patients had positive nasopharyngeal (NP) or oropharyngeal (OP) SARS-CoV-2 RT-PCR swabs. Only two patients had positive CSF SARS-CoV-2 RT-PCR, one of which showed negative NP swab testing. 48.8% of patients (*n* = 40) had cerebrovascular insults (CVIs), 28% (*n* = 23) had neuromuscular disorders (NMDs), and 23% (*n* = 19) developed CNS complications related to CNS infection or inflammation**.** 32.9% of patients (*n* = 27) were recovering, 18.3% (*n* = 15) had good outcomes, 25.6% (*n* = 21) had poor outcomes, and 18.3% (*n* = 15) died. In 23.2% of patients (*n* = 19), the neurologic syndrome was the initial presentation of COVID-19, four of which developed respiratory symptoms 2--8 days after the onset of neurologic syndrome. In two patients, the neurologic syndrome was preceded by 2--3 days of GI symptoms, while in two other patients, it was preceded only by anosmia and dysgeusia (Fig. [2](#Fig2){ref-type="fig"}**)**.Table 1Chronological summery of patients' hospital courseAuthor, YearPatients, NumberOnset of neurologic syndrome, Days^a^Respiratory failure (0 = no, 1 = yes)TreatmentOutcome (0 = no, 1 = yes)GoodRecoveringPoorDeceasedPoyiadji et al. 2020 \[[@CR12]\]13NAIVIGNANANANAMoriguchi et al. 2020 \[[@CR13]\]191Antimicrobials, steroid0010Duong et al., Haung et al. 2020 \[[@CR14], [@CR15]\]100AEDs, transient antimicrobials0100Ye et al. 2020 \[[@CR16]\]1131Antimicrobials1000Yin et al. 2020 \[[@CR17]\]1130Antimicrobials1000Filatov et al. 2020 \[[@CR18]\]111AEDs, antimicrobials0010Wong et al. 2020 \[[@CR19]\]1120Antimicrobials, gabapentin1000Zhao et al. 2020 \[[@CR20]\]^b^1-80IVIG1000Sedaghat et al. 2020 \[[@CR21]\]1140IVIGNANANANAVirani et al. 2020 \[[@CR22]\]1101IVIG0100El-Otmani et al. 2020 \[[@CR23]\]130IVIG0010Alberti et al. 2020 \[[@CR24]\]171IVIG0001Camdessanche et al. 2020 \[[@CR25]\]1111IVIGNANANANAPadroni et al. 2020 \[[@CR26]\]1241IVIG0010Scheidl et al. 2020 \[[@CR27]\]^c^1140IVIG1000Ottaviani et al. 2020 \[[@CR28]\]1101IVIG0010Abdelnour et al. 2020 \[[@CR29]\]^b^1− 70NA1000Caamaño DS et al. 2020 \[[@CR30]\]170Steroid0100Wei et al. 2020 \[[@CR31]\]^b^1− 71IVIG, steroid, antimicrobials0001Jin et al. 2020 \[[@CR32]\]1151IVF0100Suwanwongse et al. 2020 \[[@CR33]\]100IVF0100Vollono et al. 2020 \[[@CR34]\]100AEDs1000Sohal et al. 2020 \[[@CR35]\]131AEDs0001Zanin et al. 2020 \[[@CR36]\]^c^1NA1AEDs0100Paniz-Mondolfi et al. 2020 \[[@CR37]\]^d^101NA0001González-Pinto et al. 2020 \[[@CR38]\]1NA1NA0001Zhou et al. 2020 \[[@CR39]\]1241DAPs + rivaroxaban0100Valderrama et al. 2020 \[[@CR40]\]170IV tPA + thrombectomy0100Viguier et al. 2020 \[[@CR41]\]170LMWH0100Hughes et al. 2020 \[[@CR42]\]100LMWH0100Sharifi-Razavi et al. 2020 \[[@CR43]\]131NANANANANAToscano et al. 2020 \[[@CR44]\]57 (2), 10 (2), 5 (1)1 (3)IVIG (5), Plex (1)1 (1)1 (2)1 (2)0Gutiérrez-Ortiz et al. 2020 \[[@CR45]\]^e^25 (1), 3 (1)0IVIG (1)1 (2)000Chan et al. 2020 \[[@CR46]\]20 (2)1 (2)IVF01 (1)1 (1)0Bernard-Valnet et al. 2020 \[[@CR47]\]25 (1), 17 (1)NAAEDs and transient antimicrobials (2)1 (2)000Dogan et al. 2020 \[[@CR48]\]^f^6NA1 (6)Plex (6)01 (4)1 (1)1 (1)Avula et al. 2020 \[[@CR49]\].^e^42 (1), 0 (3)1 (3)Aspirin + statin (1), no acute treatment (4)01 (1)01 (3)Al Saiegh et al. 2020 \[[@CR50]\]27 (1), 0 (1)1 (2)FD stent + EVD (1), thrombectomy (1)01 (2)00Beyrouti et al. 2020 \[[@CR51]\].^b^6− 2 (1), 8 (1), 10 (1), 15 (2), 24 (1)1 (3)DAPs (1), apixaban (1), LMWH (3), IV tPA (2)001 (5)1 (1)Oxley et al. 2020 \[[@CR52]\]50 (3), 7 (1)NAAspirin (2), Apixaban (2), stent (1), DAPs (1), IV tPA (1), thrombectomy (4), hemicraniectomy (1)1 (1)1 (3)1 (1)0Tunç et al. 2020 \[[@CR53]\]44 (1), 1 (1), 7 (1), 2 (1)0DAPs (2), aspirin + low-dose LMWH (2)1 (2)2 (2)00Li et al. 2020 \[[@CR54]\]1312 (median)NALMHW (2 LVO, 2 CE, 1 CVT). AP (3 SVD, 3 LVO, 1 CE)01 (2)1 (6)1(5; one of them LVO)*AEDs* antiepileptic drugs, *DAPs* dual antiplatelet therapy, *AP* antiplatelet, *EVD* external ventricular drain, *IVF* intravenous fluid, *IVIG* intravenous immunoglobulin, *LMWH* low-molecular-weight heparin, *NA* not applicable, *Plex* plasmapheresis, *RS* respiratory symptoms like cough and or shortness of breath, *LVO* large vessel occlusion, *SVD* small vessel disease, *CE* cardioembolic, *CVT* cerebral vein thrombosis^a^Defined by onset after respiratory or gastrointestinal symptoms or anosmia or dysgeusia, if the onset of neurological presentation (zero) means that it was the initial presentation of SARS-CoV-2 infection^b^8, 7, 7, and 2 days, respectively, after the neurological presentation, the patients developed respiratory symptoms^c^The patients neurological presentation proceeded by anosmia and dysgeusia; there were no respiratory symptoms^d^5 days after neurological presentation, CXR showed BL lungs densities^e^Two patients had neurological presentation 3,2 days, respectively; after gastroenterological symptoms, there were no respiratory symptoms^f^Patients regained consciousness after the third cycle (1), second cycle (1), and first cycle (2) of plasmapheresisFig. 2CNS complications of COVID-19

Cerebrovascular complications {#Sec4}
-----------------------------

5% (*n* = 2) of the CVIs were due to cerebral vein thrombosis (CVT), 5% (*n* = 2) were intracerebral hemorrhages (ICH), 2.5% (*n* = 1) were aneurysmal subarachnoid hemorrhage and ICH, and 87.5% (*n* = 35) were ischemic stroke. Three out of 35 patients (9%) had cardioembolic stroke, five had small vessel disease stroke (14%), and 27 (77%) had large vessel occlusion (LVO) stroke. 80% (*n* = 28) of the ischemic stroke patients had elevated D-dimer levels, 57% (*n* = 20) had elevated C-reactive protein, 28.5% (*n* = 10) had elevated fibrinogen, and 14.3% (*n* = 5) were tested positive for lupus anticoagulant antibodies (Table [2](#Tab2){ref-type="table"}). Out of the 27 LVO stroke patients, seven were under the age of 50, six underwent thrombectomy, four were treated with IV tPA, six with therapeutic low-molecular-weight heparin (LMWH), three with apixaban, four with dual antiplatelets (DAPs), and one with rivaroxaban and DAPs. Six of those patients died. One of the ischemic stroke patients developed hemorrhagic conversion after thrombectomy. The LVO stroke were distributed in the following territories: left middle cerebral artery territory (MCA) (*n* = 6), right MCA (*n* = 6), left internal carotid artery (ICA) (*n* = 2), right ICA (*n* = 2), left common carotid artery (*n* = 1), basilar artery (*n* = 1), left vertebral artery (*n* = 1), left posterior cerebral artery (PCA) (*n* = 1), right PCA (*n* = 1), bilateral multiple vascular territory infarcts (*n* = 2), and unspecified (*n* = 4). Stroke with LVO was the presenting manifestation of COVID-19 in eight patients, three of which were under the age of 45 (Table [3](#Tab3){ref-type="table"}).Table 2Analysis of D-dimer, C-reactive protein, and fibrinogen levels of ischemic strokeD-dimerC-reactive proteinFibrinogen \> 500 ng/mL \[[@CR55]\] \> 2500 ng/mL \[[@CR56]\]^a^ \> 10 mg/L \[[@CR57]\] \> 41.8 mg/L \[[@CR58]\]^b^ \> 400 mg/dL \[[@CR59]\] \> 583 mg/dL \[[@CR56]\]^a^80% (*n* = 28)42.8% (*n* = 15)57% (*n* = 20)45.7% (*n* = 16)28.5% (*n* = 10)11.4% (*n* = 4)^a^According to the procoagulant profile characteristics in COVID-19 by Ranucci et al.^b^Patients with C-reactive protein level \> 41.8 mg/L are more likely to have severe complications in COVID-19 according to Liu et al.Table 3Summary of the cerebrovascular complications of COVID-19Author, yearAge (year), sexSARS-CoV-2Neurological presentationNeurological investigationsNeurological diagnosisCSF and othersNasal swabCSFGonzález-Pinto et al. 2020 \[[@CR38]\]^a^36, FPosNAAphasia, right side hemiplegia. She was found down in her apartmentCT and CTA: Occlusion of left ICA, MCA, ACALeft ICA strokeCRP 156 mg/L. D-Dimer 7540 ng/mLZhou et al. 2020 \[[@CR39]\]75, FPosNALeft hemiplegia and right hemiparesisCT: bilateral cerebral infarctsRight MCA and ACA stroke. Left ACA stroke. Bilateral legs DVTsCRP: 42.52 mg/LD-dimer \> 8000 ng/mLValderrama et al. 2020 \[[@CR40]\]52, MPosNARight hemiparesis and aphasia. Left gaze, right partial hemianopia, facial weaknessCT: left MCA hyperdense signCTA: left ICA occlusionCTP: favorable mismatch ratio of 4.1Left ICA strokeCRP 11 mg/L. D-dimer \> 10,000 ng/mL. Fibrinogen 235 mg/dLViguier et al. 2020 \[[@CR41]\].^b^66, MPosNARight hemiparesis and aphasiaCT: left frontal hypoattenuationCTA: left CCA intraluminal floating thrombusMultiple scattered infarcts within left carotid territoryCRP 219 mg/L. D-dimer 2220 ng/mL. fibrinogen 820 mg/dLHughes 2020. et al. \[[@CR42]\]59, MPosNARight fronto-temporal headache followed by right sided weakness and numbnessCTV: Filling defect in the right sigmoid and transverse sinusCVTCRP: 20 mg/l. APTT: 19.7. Fibrinogen 490 mg/dLSharifi-Razavi et al. 2020 \[[@CR43]\]^c^79, MPosNAAcute loss of consciousnessCT: right hemispheric massive intracerebral hemorrhage with intraventricular and subarachnoid hemorrhageICHCRP 10 mg/L. INR 1. PTT 64 sAuthor, yearMean age (year)Patients, NumberMale/female, NumberSARS-CoV-2Neurological presentationNeurological investigationsNeurological diagnosisNasal swabCSFAvula et al. 2020 \[[@CR49]\]^d^8141/3Pos (4)NA1. AMSCT head and CTA. CRP 260 mg/LLeft MCA stroke2. Dysarthria, left facial droop, left hemiparesis and hemineglectCT head and CTARight MCA stroke3. AMS, left hemiparesisCT head, CTA, CTPCRP 162.4 mg/L. D-dimer 13,966 ng/mLRight ICA stroke4. Fifteen minutes of right arm weakness, numbness, aphasiaMRI (positive for stroke) and MRA. D-dimer 3,442 ng/mLTIA/Left MCA strokeAl Saiegh et al. 2020 \[[@CR50]\]^e^46.521/1Pos (2)Neg (2)1. Sudden headache, loss of consciousnessCT head, conventional angiography and CSF testingPosterior fossa aneurysmal SAH and ICH2. Right hemiparesis, aphasiaCT head, CTA and CSF testingLeft MCA strokeBeyrouti et al. 2020 \[[@CR51]\]^f^69.3365/1Pos (6)NA1. Left arm incoordination, 7 days later, bilateral incoordination and right homonymous hemianopiaMRI brain. Pos lupus anticoagulant, D-dimer \> 80,000 ng/mL. CRP 305.4 mg/L. Fibrinogen 950 mg/dLLeft vertebral artery occlusion- \> left PICA stroke- \> 7 days later left PCA stroke2. Confusion, incoordinationCT head, Pos lupus anticoagulant. D-dimer 7,750 ng/mL. CRP 150.1 mg/L. Fibrinogen 703 mg/dLLeft cerebellar and right parietooccipital infarcts3. Dysarthria, right hemiparesisCT head, Neg lupus anticoagulant, D-dimer 16,100 ng/mL. CRP 161.2 mg/L. Fibrinogen 530 mg/dLLeft PCA stroke4. Dysarthria, left hemiparesisMRI brain. Pos lupus anticoagulant, D-dimer 27,190 ng/mL. CRP 12.8 mg/L. Fibrinogen 463 mg/dLRight MCA stroke5. Dysarthria, left hemiparesisCT head and CTA. Pos lupus anticoagulant, D-dimer 19,450 ng/mL. CRP 27.7 mg/L. Fibrinogen 496 mg/dLRight MCA stroke6. Dysphasia, right hemiparesisMRI. Pos lupus anticoagulant, D-dimer 1,080 ng/mL. CRP 179.9 mg/LBasilar artery thrombus and bilateral P2 stenosisOxley et al. 2020 \[[@CR52]\]^g^40.454/1Pos (5)NA1. Left hemiplegia, homonymous hemianopia, right gaze preferenceCT, CTA, CTP, MRI. D-dimer 460 ng/mL, Fibrinogen 501 mg/dLRight ICA stroke2. AMS, dysphasia, right hemiplegiaCT, CTA, MRI. D-dimer 52 ng/mL, Fibrinogen 370 mg/dLLeft MCA stroke3. AMS, left hemiplegia, homonymous hemianopia, right gaze preference, ataxiaCT, CTA, CTP, MRI. D-dimer 2230 ng/mL, Fibrinogen 739 mg/dLRight PCA stroke4. AMS, global aphasia, right hemiplegia, left gazeCT, CTA, MRI. D-dimer 1388 ng/mL, Fibrinogen 443 mg/dLLeft MCA stroke5. AMS, left hemiplegia, dysarthria, left facial droopCT, CTA, CTP. D-dimer 1750 ng/mL, Fibrinogen 531 mg/dLRight MCA strokeTunç et al. 2020 \[[@CR53]\]65.2542/2Pos (4)NA1. Left hemiparesis, dysarthria, left facial droopMRI brain. D-dimer 803 ng/mL. CRP 142 mg/LRight MCA stroke2. Right hemiparesis, dysarthriaMRI brain. D-dimer 1040 ng/mL CRP 4 mg/LLeft lenticulostriate artery infarction3. Right hemiparesis, loss of consciousnessMRI brain. D-dimer 644 ng/mL. CRP 33 mg/LLeft MCA stroke4. Left hemi-hypoesthesia, mild ataxiaMRI brain. D-dimer 378 ng/mL. CRP 366 mg/LRight pontine infarctionLi et al. 2020 \[[@CR54]\]^h^71.61137/6Pos (13)NANo neurological presentations were reportedCTV (1), CT head (1 R MCA and 1 L BG hg). CRP (median) 51.1 mg/L (13). D-dimer (median) 6900 ng/mL (13)ICH (1). CVT (1). LVO (5). SVD stroke (3). CE stroke (3)*AMS* altered mental status, *ACA* anterior cerebral artery, *CCA* common carotid artery, *COVID-19* Coronavirus disease 2019, *CT* computed tomography, *CTA* CT angiography, *CTP* CT perfusion, *CTV* CT venogram, *DVT* deep vein thrombosis, *DWI* diffusion weighted images, *ICA* Internal carotid artery, *ICU* intensive care unit, *INR* international normalized ratio, *LDH* Lactate dehydrogenase, *MCA* middle cerebral artery, *MRI* magnetic resonance imaging, *NA* not applicable, *Neg* negative, *Pos* positive, *RT-PCT* real-time polymerase chain reaction, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *T2WI/FLAIR* T2-weighted images/fluid attenuation inversion recovery, *CRP* C-reactive protein, *PTT* partial thromboplastin time, *WBCs* white blood cells, *CSF* cerebral spinal fluid, *ICH* intracerebral hemorrhage, *CVT* cerebral vein thrombosis, *L* left, *R* right, *PICA* posterior inferior cerebellar artery, *PEs* pulmonary embolisms, *LVO* large vessel occlusion, *SVD* small vessel disease, *CE* cardioembolic, *CVT* cerebral vein thrombosis, *WM* white matter, *AIDP* acute inflammatory demyelinating polyradiculoneuropathy^a^The patient had free medical history but smoker. CTA revealed free-floating thrombus in the ascending aorta with no signs of aortic atheromatosis^b^Antiphospholipid antibodies were negative^c^The patient did not have history of hypertension or anticoagulation therapy. Platelets of 210 × 10^9^/L^d^Case \# 4: MRI/MRA revealed left medial temporal lobe small infarct and left M1 stenosis^e^After 10 days, patient\#2 presented with hemorrhagic conversion and hydrocephalus^f^Patient 1 and 4 had PEs. Patient 2 INR was 3.6 (patient was already on warfarin). Patient 6 had right thalamus, left pons, right occipital lobe and right cerebellar infarcts. One patient had non-treated atrial fibrillation, 1 had treated atrial fibrillation, and 1 had previous stroke;^g^2 patients had diabetes, and 1 patient had hyperlipidemia and hypertension^h^9 out 13 patients had hypertension, 6 out of 13 had diabetes mellitus, 3 out of 13 had cardiovascular disease, 1 out of 13 had malignancy, and 11 out of 13 had severe COVID-19 with multiorgan failure

Neuromuscular complications {#Sec5}
---------------------------

17.4% (*n* = 4) of the NMDs patients had rhabdomyolysis, 4.3% (*n* = 1) had polyneuritis cranialis, 4.3% (*n* = 1) had oculomotor nerve palsy, and 73.9% (*n* = 17) had Guillain--Barre syndrome (GBS). Seven out of the seventeen GBS cases had facial weakness, one of which manifested with isolated facial diplegia. In two cases, GBS was the first presentation of SARS-CoV-2 infection, while in 14 other patients, GBS developed 3--24 days after the onset of flu-like symptoms. One patient presented 2 weeks after anosmia and ageusia without respiratory or GI symptoms. Electrophysiologic studies showed evidence of acute motor and sensory axonal variants (AMSAN) in five patients, mixed axonal and demyelinating patterns in two patients, and demyelinating patterns in six patients. EMG was not performed in four patients, one of which was diagnosed with Miller Fisher syndrome and positive serum GD1b-IgG antibody. CSF studies revealed albuminocytologic dissociation in ten patients, were normal in three patients (protein \< 45 mg/dL, WBCs 0--5 cells/μl). In one patient, CSF protein and WBCs were 54 mg/dL and 9 cells/μL respectively, and CSF was not performed in three patients. 14 out of 17 patients received IVIG, one patient received IVIG and plasmapheresis, one patient showed spontaneous recovery, and one patient received prednisone. Six out of the seventeen patients developed respiratory failure, one of which died (Table [4](#Tab4){ref-type="table"}).Table 4Summary of the neuromuscular complications of COVID-19Author, yearAge (year), sexSARS-CoV-2Neurological presentationNeurological investigationsNeurological diagnosisCSF and othersNasal swabCSFZhao et al. 2020 \[[@CR20]\]61, FPosNALegs and arms weaknessAreflexiaDay 5 EMG/NCS revealed demyelinating patternGBSCSF: protein124 mg/dL. Cell counts 5 cells/μLSedaghat et al. 2020 \[[@CR21]\]65, MPosNAAscending quadriparesis. Bifacial nerve palsy. AreflexiaDay 9 EMG/NCS revealed axonal patternGBS variant---AMSANCSF was not performedVirani et al. 2020 \[[@CR22]\]54, MPosNAAscending weakness and Paresthesia. AreflexiaT& L spine MRI was normal. EMG/NCS were not performedGBSCSF was not performedEl-Otmani et al. 2020 \[[@CR23]\]70, FPosNegQuadriplegia. Hypotonia. AreflexiaDay 10 EMG/NCS revealed axonal patternGBS variant---ASANCSF: protein 100 mg/dL. Normal WBCAlberti et al. 2020 \[[@CR24]\]71, MPosNegAscending weakness and paresthesia. AreflexiaEMG/NCS revealed mixed axonal and demyelinating patternsGBS---mixed damageCSF: protein 54 mg/dL. WBCs 9 cells/μLCamdessanche et al. 2020 \[[@CR25]\]^a^64, MPosNAFlaccid tetraparesia and paresthesia. AreflexiaDay 5 EMG/NCS revealed demyelinating patternGBSCSF: protein 166 mg/dL. Normal WBCsPadroni et al. 2020 \[[@CR26]\]70, FPosNAGait difficulty and paresthesia. AreflexiaEMG/NCS revealed demyelinating patternGBSCSF: protein 48 mg/dL. WBCs 1 cells/μLScheidl et al. 2020 \[[@CR27]\]54, FPosNAParaparesis. AreflexiaAdmission EMG/NCS revealed demyelinating patternGBSCSF: protein 140 mg/dL. Normal WBCsOttaviani et al. 2020 \[[@CR28]\]66, FPosNegDifficulty walking, paraparesis. Areflexia then quadriparesis and facial weaknessDay 10 EMG/NCS revealed mixed axonal and demyelinating patternsGBS---mixed damageCSF: protein 108 mg/dL. Normal WBCs. Serum anti-glycolipid antibodies were absentAbdelnour et al. 2020 \[[@CR29]\]69, MPosNABilateral lower limb weakness. AreflexiaBrain and spine MRIs were normal. EMG/NCS were not performedGBSCSF was not performedCaamaño DS et al. 2020 \[[@CR30]\]61, MPosNegBilateral facial weakness. Unresponsive blink reflex on both eyesBrain MRI and CT were normal. EMG/NCS were not performedAtypical GBS variant---Facial diplegiaCSF: protein 44 mg/dL. WBCs 0 cellsWei et al. 2020 \[[@CR31]\]62, MPosNABinocular diplopia and left ptosis. Left eye was down and out at rest. No anisocoria. No areflexiaBrain MRI and MRA were negativeLeft oculomotor nerve palsyCSF was not performed. CRP 142.21 mg/LJin et al. 2020 \[[@CR32]\]61, FPosNAMuscle tenderness and weakness of lower extremitiesEMG/NCS were not performedRhabdomyolysisMyoglobin \> 12,000.0 μg/L. CK 11,842 U/L. LDH 2,347 U/L. CRP 111 mg/LSuwanwongse et al. 2020 \[[@CR33]\]88, MPosNABilateral thighs weakness and painEMG/NCS were not performedRhabdomyolysisCK 13,581 U/L. LDH 364 U/LAuthor, YearMean age (years)Patients, NumberMale/female, NumberSARS-CoV-2Neurological presentationNeurological investigationsNeurological diagnosisNasal swabCSFToscano et al. 2020 \[[@CR44]\]^b^58.454/1Pos (4)Neg (1)Neg (5)Tetraparesis (2), paraplegia (1), paresthesia (2), facial weakness (4), ataxia (2). Areflexia (5)Days 3--12 EMG/NCS: axonal (3), demyelination (2). MRI: caudal nerves enhancement (2), facial nerves enhancement (1), normal (2)GBS: AMSAN variant (3), AIDP variant (2)Gutiérrez-Ortiz et al. 2020 \[[@CR45]\]^c^44.522/0Pos (2)Neg (2)1. Vertical diplopia, perioral paresthesia, gait instability. AreflexiaPos GD1b-IgG antibodyCSF: protein 80 mg/dL, WBCs 0 cells. No EMG was performedMiller Fisher syndrome (right INO and right fascicular oculomotor palsy)2. Diplopia. AreflexiaCSF: protein 62 mg/dL, WBCs 2 cells /μLPolyneuritis cranialis (bilateral abducent nerve palsy)Chan et al. 2020 \[[@CR46]\]7321/1Pos (2)NAGeneralized weakness (2), leg twitching (1)Serum (ave): CK 2313 U/L: LDH 517.5 U/L. CRP: 11.25 mg/dLRhabdomyolysis*GBS* Guillain--Barre syndrome, *AMSAN* acute motor-sensory axonal neuropathy, *CK* creatine kinase, *CMAP* compound muscle action potential, *COVID-19* Coronavirus disease 2019, *EMG* electromyography, *ICU* intensive care unit, *LDH* lactate dehydrogenase, *MRI* magnetic resonance imaging, *NA* not applicable, *NCS* nerve conduction studies, *Neg* negative, *Pos* positive, *OCBs* oligoclonal bands, *PMN* polymorphonuclear cells, *RT-PCT* real-time polymerase chain reaction, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *SNAP* sensory nerve action potential, *T2WI/FLAIR* T2-weighted images/fluid attenuation inversion recovery, *CRP* C-reactive protein, *PTT* partial thromboplastin time, *WBCs* white blood cells, *Ave* average, *CSF* cerebral spinal fluid^a^Negative serum anti-gangliosides^b^CSF: protein (mg/dL): 101, 123, 193, normal protein, 40. WBCs (cells per mm^3^): 4,0,0,0,3. Antiganglioside antibodies: negative (3), not tested (2)^c^Case\#1: Exam revealed limited adduction and downgaze movements of his right eye, and left eye nystagmus on left gaze. Case\#2: Exam revealed limited abduction in both eyes, and fixation nystagmus, with the upper gaze more impaired

CNS infectious or inflammatory complications {#Sec6}
--------------------------------------------

We identified 19 cases with confirmed COVID-19 which were suspected to have encephalitis, based on the presence of one of the following criteria: (a) meningeal signs, (b) altered mental status, focal neurological signs, or seizures, without better alternative explanation, or (c) suggestive MRI findings. 68.4% (*n* = 13) were ultimately diagnosed as meningoencephalitis, 5.3% (*n* = 1) as rhombencephalitis, 5.3% (*n* = 1) as acute necrotizing hemorrhagic encephalopathy, 5.3% (*n* = 1) as encephalopathy, 10.5% (*n* = 2) presented with status epilepticus, one of which was focal, and 5.3% (*n* = 1) had CNS demyelinating lesions. In the 13 meningoencephalitis cases, only four CSF samples revealed lymphocytic pleocytosis, two of which had positive CSF SARS-CoV-2 RT-PCR. Nine patients developed respiratory failure, six received plasmapheresis, and one died. One patient showed postmortem evidence of the presence of viral particles in the neurons and capillary endothelial cells in the frontal lobe (Table [5](#Tab5){ref-type="table"}).Table 5Summary of the CNS infectious or inflammatory-related complications of COVID-19Author, YearAge(years), SexSARS-CoV-2Neurological presentationNeurological investigationsNeurological diagnosisCSF and othersNasal swabCSFPoyiadji et al. 2020 \[[@CR12]\]^a^58, FPosNAAltered mental status (AMS)MRI: Hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regionsAcute hemorrhagic necrotizing encephalopathyCSF was negative for HSV-1 and 2, VZV and West Nile PCRsMoriguchi et al. 2020 \[[@CR13]\]^b^24, MNegPosHeadache then unconsciousness, generalized convulsions and neck rigidityT2WI/FLAIR: hyperintensityin the right mesial temporal lobe and hippocampusMeningitis/encephalitisventriculitisCSF: OP \> 32 cmH~2~O, 12 mononuclear cells, 2 PMNs, CSF HSV-1 PCR was not testedDuong et al., Haung et al. 2020 \[[@CR14], [@CR15]\]^c^41, FPosPosHeadache, new onset seizure, neck stiffness, fever and photophobiaCT head was normalEEG: Generalized slowing with no epileptic dischargesMeningoencephalitisCSF: protein 100 mg/dL. WBCs 70 cells/μL 100% lymphocyte. Glucose 120Ye et al. 2020 \[[@CR16]\]^d^No age, MPosNegMyalgia and confusion. Nuchal rigidity, positive Kernig sign and Brudzinski signCT head was normalEncephalitisCSF: OP 220 mmHg. Normal WBC, protein and glucoseYin et al. 2020 \[[@CR17]\]64, MPosNegAMS, neck stiffness. Positive clonus, Babinski, Chaddock and Brudzinski signsCT head was normalEncephalitisCSF: OP 200 cmH~2~O. protein, WBCs and glucose were normalFilatov et al. 2020 \[[@CR18]\]^e^74, MPosNAHeadache and AMSEEG: bilateral slowing and focal slowing in the left temporal region with sharply contoured wavesEncephalopathyCSF: protein 68 mg/dL. WBCs 4 cells/μLWong et al. 2020 \[[@CR19]\]^f^40, MPosNAAtaxia, diplopia, oscillopsia, hiccups, right arm paresthesiaMRI: T2 hyperintensity of the right inferior cerebellar peduncle and upper cord associated with microhemorrhagesRhombencephalitisCSF: normal WBC, protein and glucoseVollono et al. 2020 \[[@CR34]\]^g^78, FPosNAMyoclonic jerks of the right face and right limbs. FeverEEG: semi-rhythmic, irregular, high amplitude delta activity, predominantly over the left fronto-centro-temporal regionsFocal status epilepticusCSF was not performedSohal et al. 2020 \[[@CR35]\]72, MPosNAAMS, episodes of tonic colonic movementsCT head: no acute findingsEEG: Six left temporal seizures and left temporal sharp wavesStatus epilepticusCSF was not performedZanin et al. 2020 \[[@CR36]\]^h^54, FPosNegAMSMRI: Periventricular confluent white matter hyperintensityEEG: Two focal fronto-temporal seizuresDemyelinating lesionsCSF: normal WBC, protein and glucose. No OCBs were sentCRP 41.3 mg/L[Paniz-Mondolfi]{.ul} et al. 2020 \[[@CR37]\]74, MPosNAConfusion and fallsCT head: no acute findingsAutopsy revealed 80 to 110 nm viral particles in frontal lobe brain (neurons and endothelial cells)Postmortem presence of virus in neural and capillary endothelial cells in frontal lobe from a patient infected with COVID-19CRP 183.5 mg/L. D-dimers 2925 ng/mLAuthor, yearMean age (years)Patients, numberMale/female, numberSARS-CoV-2Neurological presentationNeurological investigationsNeurological diagnosisNasal SwabCSFBernard-Valnet et al. 2020 \[[@CR47]\]^i^65.520/2Pos (2)Neg (2)1. tonic--clonic seizure. Verbal and motor perseverationsEEG: status epilepticusMRI brain: normalCSF: protein 46.6 mg/dL, WBCs 17 cells /mm^3^ (97% lymphs)Meningoencephalitis2. Intense headache and AMS. Left hemianopia and sensory hemineglectMRI brain: normalCSF: 46.1 mg/dL, WBCs 21 cells /mm3 (89% lymphs)MeningoencephalitisDogan et al. 2020 \[[@CR48]\]^j^49.165/1Pos (6)Neg (6)Failure to recover consciousness or severe agitation during weaning from mechanical ventilation (6)MRI: Cortical or WM hyperintensities, contrast enhancement, and sulcal hemorrhages (3)Autoimmune Meningoencephalitis*AMS* altered mental status, *OP* opening pressure, *CK* Creatine Kinase, *CMV* Cytomegalovirus, *COVID-19* Coronavirus disease 2019, *CT* Computed tomography, *DWI* Diffusion Weighted Images, *EEG* Electroencephalography, *HSV* Herpes Simplex Virus, *ICU* Intensive-care unit, *LDH* Lactate dehydrogenase, *MRI* Magnetic Resonance Imaging, *NA* not applicable, *Neg* negative, *Pos* positive, *OCBs* oligoclonal bands, *PMN* Polymorphonuclear cells, *RT-PCT* Real-Time Polymerase Chain Reaction, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *T2WI/FLAIR* T2-weighted Images/Fluid Attenuation Inversion Recovery, *VZV* Varicella Zoster Virus, *CRP* C-reactive protein, *WBCs* white blood cells, *CSF*: cerebral spinal fluid, *WM* white matter^a^CSF analysis was limited due to traumatic LP^b^DWI: hyperintensity along the wall of the inferior horn of the right lateral ventricle^c^SARS-CoV-2 infection was entirely confined to the central nervous system^d^CSF anti-SARS-CoV-2 IgM and IgG were not detected^e^CT head revealed left PCA distribution encephalomalacia. CSF was negative for bacterial cultures, HSV PCR, RSV, and CMV PCR^f^Myelin oligodendrocyte glycoprotein antibody (MOG-IgG) and aquaporin 4 antibody results were requested, but no results reported^g^The patient has history of well-controlled post-encephalitic epilepsy^h^MRI also reveals bulbo-medullary and C2-T6 focal intramedullary hyperintensities. No contrast enhancement^i^Case\#1 Negative CSF anti-NMDA antibodies. Case \#1&2: Negative HSV/VZV PCRs^j^Serum ferritin levels remarkably improved post-plasmapheresis in recovering patients. CSF (median): protein 69.4 mg/dL. WBCs 0 cells/μL. Glucose 116. OCBs neg (5)

Discussion {#Sec7}
==========

Our systematic review indicates that SARS-CoV-2 infection is not solely a respiratory illness, as neurological complications are not rare. Ischemic and hemorrhagic stroke, Guillain--Barre syndrome, and its variants, encephalitis, and seizure have all been observed, which emphasizes the importance of neurological surveillance. In an analysis of 214 cases of COVID-19 in Wuhan, China, 78 (36.4%) had neurological complications. Patients with severe infection were more likely to have neurological manifestations like alteration in sensorium and muscle weakness (45.5% Vs 30.2% in non-severe). The manifestations involved both the central and peripheral nervous system. The severity of these manifestations ranged from acute cerebrovascular disease and impaired consciousness to dizziness and headache \[[@CR60]\].

Cerebrovascular complications {#Sec8}
-----------------------------

In our review, ischemic stroke was the most common neurological manifestation, occurring in 42.7% of the subjects, with LVO representing 77% of the ischemic stroke. According to a series of 388 COVID-19 patients from Italy, thromboembolic events occurred in 21% of the patients, including venous thromboembolism, ischemic stroke, and acute coronary syndrome \[[@CR61]\]. The exact mechanism of the hypercoagulable state is not well understood. D-dimers might play a major prothrombotic role in COVID-19 patients. In this review, 80% of the ischemic stroke patients had elevated D-dimer levels, which are independently associated with poor outcome \[[@CR62]\]. Severe COVID-19 respiratory infection often leads to sepsis induced hypercoagulability, evident by increased intravascular platelet activation, increased fibrinogen, and mild prolongation of PT and aPTT \[[@CR63]\]. Indeed, a study in Wuhan, China, showed that 71.4% of patients who died of COVID-19 had disseminated intravascular coagulation (DIC) \[[@CR62]\] Moreover, SARS-CoV-2 virus is known to bind angiotensin-converting enzyme 2 (ACE2) on endothelial cells which promotes a proinflammatory and vasoconstrictive state of endothelial dysfunction leading to end organ damage, including stroke. ACE2 recombinant therapy, therefore, may be a promising targeted therapy for COVID-19-related stroke \[[@CR64]\]. Transient production of antiphospholipid antibodies may also play a role. In a study by Harzallah et al., 25 out of 56 patients with confirmed or suspected SARS-CoV-2 infection were positive for lupus anticoagulants, and five patients had either anticardiolipin or anti--β2-glycoprotein I antibodies \[[@CR65]\]. Zhang et al. detected antiphospholipid antibodies in three COVID-19 patients; all of them had multiple cerebral infarcts \[[@CR66]\]. In this review, five of the LVO stroke tested positive for lupus anticoagulant.

When presenting in the appropriate time window, thrombolytic treatment of COVID-19 patients with ischemic stroke is reasonable. The role of anticoagulation, like LMWH, in this clinical context is still unclear \[[@CR64]\]. Harzallah et al. recommended early anticoagulation therapy for individuals with SARS-CoV-2 infection and positive lupus anticoagulant \[[@CR65]\]. Previous investigations suggested that COVID-19 is associated with both platelet and clotting cascade activation \[[@CR67]\]. Further clinical trials are necessary to determine the role of antiplatelets and/or anticoagulation for the treatment and prevention of thrombotic events in COVID-19, including milder cases.

Neuromuscular complications {#Sec9}
---------------------------

Previously identified coronaviruses, including SARS-CoV-1 and MERS, were associated with GBS \[[@CR68]\]. In our review, neuromuscular disorders are the second most commonly encountered neurological complication of SARS-CoV-2 infection (28%), especially GBS. The mechanisms of GBS related to SARS-CoV-2 are still incompletely understood. Both para- and post-infectious mechanisms were proposed \[[@CR20], [@CR26]\]. Two patients, in our review, did not experience preceding fever, respiratory, or GI symptoms and GBS was the initial presentation. This suggests a para-infectious process, as has been reported recently with Zika virus \[[@CR69]\]. One possible immunological explanation is the cytokine release syndrome (CRS), caused by an exacerbated recruitment and activation of macrophages, neutrophils, and natural killer cells (NK) in response to SARS-CoV-2 infection. Cytokines involved in CRS include IL-1β, IL-1Ra, IL-6, IL-17, TNF-α, CCL2, and sIL2-Rα; a critical step in the process is binding of IL-6 to IL-6R (sIL-6R) causing JAK-STAT3 activation, and subsequent secretion of vascular endothelial growth factor (VEGF), monocyte chemoattractant protein--1 (MCP-1), IL-8, and more IL-6, as well as decreased E-cadherin expression \[[@CR70], [@CR71]\]. This cytokine storm can produce extensive tissue damage, including the peripheral nervous system \[[@CR72]\], and appears to correlate with COVID-19 severity. Accordingly, several therapeutic options are under study, with the intent to stabilize the immune system in COVID-19 and either prevent or minimize the consequences of this storm, as reviewed by Diamanti et al. \[[@CR73]\]

A second mechanism explaining GBS in COVID-19 may be production of antibodies against ganglioside components of the peripheral nerves, owing to molecular mimicry with surface antigens of the infectious pathogen. This mechanism explains GBS following Campylobacter jejuni infection \[[@CR74]\], which is frequently associated with axonal findings on electrophysiology. Similar molecular mimicry phenomena may occur in COVID-19 \[[@CR75]\], and in fact, five cases in our review were electrophysiologically characterized as AMSAN, yet the exact frequency of ganglioside antibodies remains unknown, because those antibodies were not tested in most cases that we reviewed. Furthermore, sporadic reports of other autoimmune complications in the context of SARS-CoV-2 infection, such as steroid responsive encephalitis \[[@CR76]\], immune thrombocytopenic purpura \[[@CR77]\], and autoimmune hemolytic anemia \[[@CR78]\], suggest that SARS-CoV-2 infection may serve as a trigger for autoimmune disorders.

With the emergence of more cases of acute neuropathies temporally linked to SARS-CoV-2 infection, we should gain a better understanding of the underlying pathophysiology and potential therapeutic options of GBS related to COVID-19. Since these neuropathies are treatable and they pose increased morbidity and mortality, neurologists, intensivists, and internists working with COVID-19 patients must be vigilant of this association.

CNS infection by COVID-19 {#Sec10}
-------------------------

Coronavirus can be neuroinvasive and cause direct CNS infection; this was convincingly demonstrated by the detection of particles and/or RNA of SARS-CoV-1, a virus with 79% genetic homology to SARS-CoV-2 \[[@CR79]\], in human autopsies \[[@CR80], [@CR81]\]. Likewise, two of the cases that we reviewed showed positive CSF SARS-CoV-2 PCR \[[@CR13], [@CR15]\], and one \[[@CR37]\] documented the evidence of viral particles in the neurons and capillary endothelial cells of the frontal lobe in a postmortem examination. The authors concluded that there was an active viral entry across the brain microvasculature into the neurons, as there was blebbing of viral particles coming in and out of the endothelial membrane \[[@CR37]\]. Mechanistically, SARS-CoV-2 virus may enter the CNS through hematogenous route or retrograde synaptic transmission. The ACE 2 protein, which functions as a receptor for SARS-CoV-2, is abundantly expressed in the endothelial cells, supporting glia and neurons, and might be the binding site facilitating hematogenous entry. The systemic hyper-inflammation increases the permeability of the blood--brain and blood-CSF barriers, which might facilitate CNS entry, as well \[[@CR82], [@CR83]\]. Retrograde synaptic transmission may occur via the olfactory nerve \[[@CR84]\]. This possibility is supported by the fact that anosmia is a frequent early sign of COVID-19 \[[@CR85]\]. It has been proposed that SARS-CoV-2 neurotropism may explain not only the common symptoms of encephalitis, but also the respiratory failure, by involvement of the medullary respiratory centers. This mechanism has been demonstrated in animal models, but not yet in humans \[[@CR86]\].

It should be noted, however, that in most cases of suspected "meningoencephalitis", the virus could not be detected in the CSF. There are several potential explanations for this negative result. One is that the encephalitis in COVID-19 is more often immune-mediated, resulting from post-infectious or para-infectious mechanisms, and cytokine dysregulation, as previously discussed in GBS, rather than a result of direct viral invasion \[[@CR83]\]. The response of the encephalitic syndrome to plasmapheresis in five cases \[[@CR48]\] supports this notion, as does the occurrence of acute necrotizing encephalopathy in one case \[[@CR12]\]. Acute necrotizing encephalopathy was previously described following influenza and other viral infections and attributed to cytokine storm \[[@CR87]\]. A second explanation is that the virus may cause endothelial injury and induce a thrombotic microangiopathy (TMA)-like state, which can lead to severe encephalopathy with no evidence of inflammation based on CSF studies. A third theory is that PCR testing in the CSF has suboptimal sensitivity for the detection of SARS-CoV-2. This limitation of PCR is well known to neurologists, as it occurs with several other neuroinvasive viruses, including West Nile Virus \[[@CR88]\], and enterovirus-D68 causing acute flaccid myelitis \[[@CR89]\]. Detection of intrathecal virus-specific antibodies and their ratio to serum antibodies, and the recently developed metagenomic sequencing technology \[[@CR90], [@CR91]\], may increase the sensitivity of viral detection in the CSF in those cases, and it would be interesting to explore the utility of those techniques in COVID-19 in the near future. Detailed investigations, including CSF studies, imaging, and, when possible, autopsy, are required to better elucidate those mechanisms.

Epileptic complications {#Sec11}
-----------------------

Although two COVID-19 patients in our review presented with status epilepticus, one of them had an established history of epilepsy from another cause. Lu et al. studied 304 COVID-19 patients and concluded that none of these patients had acute symptomatic seizures or status epilepticus \[[@CR92]\]. The available data are too limited to make conclusions about the association of COVID-19 with development of seizures. Nevertheless, patients with severe SARS-CoV-2 infection, especially those hospitalized in intensive care units, are at risk for subclinical seizures or nonconvulsive status epilepticus (NCSE), owing to polypharmacy, metabolic derangements, toxemia, hypoxic-anoxic brain injury, or less commonly stroke or encephalitis related to SARS-CoV-2 infection. Therefore, continuous video EEG monitoring may be warranted in selected cases, as delayed diagnosis and treatment of NCSE will increase morbidity and mortality \[[@CR93]\].

Finally, Lovati et al. reported a case of HSV-1 encephalitis, where the diagnosis and treatment were delayed because of anchoring on COVID-19 and its neurological complications \[[@CR94]\]. Despite all the reports of COVID-19 neurological complications, other pathologies are still more common. Ignoring this would result in significant delays in diagnosing and treating neurological patients.

A number of recently published systematic reviews on COVID-19 have addressed the same topic (Table [6](#Tab6){ref-type="table"}). The novelty of our review lies in the breadth of coverage, allowing it to serve as a primer for neurologists by summarizing the most recent evidence and the most important and relevant practical points. However, our study has some limitations. First, most of the used evidence is based on single case reports or small series, which limits its generalizability. Second, some case reports did not complete or report the full work-up required to exclude alternative causes of the neurological syndrome presented. Third, many cases are reported from specific ethnic populations, and hence, several demographics, genetic, or microbiologic variables might preclude the applicability of the conclusions in different populations. Fourth, several stroke patients had multiple comorbidities and potentially causative vascular risk factors that we did not include in our analysis. Fifth, due to incomplete work-up of several of the ischemic stroke studies included in the review, we did not have enough data for accurate stroke mechanism classification per TOAST in several cases. Last but not least, because of the small number of subjects studied and the suboptimal quality of study design, it is not possible to reach firm conclusions about the causal effect of COVID-19 for some neurological disorders.Table 6Summary of previous systematic reviews of the neurological manifestations of SARS-CoV-2Author, yearGoalsSearch dateReviewed studiesReviewed pathologiesConclusionsComments/limitationsWhittaker et al., 2020 \[[@CR95]\]To provide a comprehensive review of the neurological manifestations of SARS-CoV-2 and its effect on mortalityNot reported. Submitted on April 30, 2020Thirty-one studies: 13 case reports, 2 observational studies, 13 retrospective, 2 prospective and 1 cross-sectional studyOlfactory and gustatory dysfunction, Headache, encephalopathy, seizure, GBS, CVAMore data is required to correlate the neurological manifestations to SARS-CoV-2 infectionVery well-written paperLimited number of studies on cerebrovascular diseaseMontalvan et al., 2020 \[[@CR96]\]To review the neurological aspects of SARS-CoV-2 and other coronavirusesApril 2020Sixty-seven studies: 12 systematic reviews, 15 experimental model studies, 21 series, 3 cases and controls and 16 case reportsOnly 11 of the reviewed studies were related to the novel SARS-CoV-2. The rest were related to other coronavirusesEncephalitis, demyelination, polyneuropathy, CVASARS-CoV-2 might be neuropathogenic, but underdiagnosedNot limited to SARS-CoV-2. Limited description of the clinical manifestations which limits its use as a reference for cliniciansLeonardi et al., 2020 \[[@CR97]\]To prove the presence of central and peripheral nervous system manifestations in CoronavirusApril 5, 202029 studies were examinedCVA, GBS, hypogeusia, hyposmia, encephalopathy, encephalitis, rhabdomyolysis, seizureProspective cohorts are needed to identify any long-term neurological complications of SARS-CoV-2. Recommended open data sharing between centersLimited description of the clinical manifestations which limits its use as a reference for cliniciansAsadi-Pooya et al., 2020 \[[@CR98]\]To discuss the evidence of CNS involvement in SARS-CoV-2March 26, 2020Two main studies identified (a narrative review and a viewpoint). Six other reports were extracted from their reference listsCVA, headache, confusion, dizziness, ataxia, seizuresIt is very likely that patients with severe infection would have neurological manifestations of SARS-CoV-2Limited number of studiesDid not describe the clinical manifestations which limits its use as a reference for cliniciansMunhoz et al., 2020 \[[@CR99]\]To point out the main neurological manifestations of SARS-CoV-2 with their epidemiology, pathophysiology, and clinical findingsMay 10, 2020Thirty-seven studies. Including case reports and series, retrospective studies, and a prospective studyCVA, encephalopathy, GBS, anosmia, ageusia, myalgias, headacheNeurological manifestations occur in \> 1/3 of the hospitalized patients with variable severity. SARS-CoV-2 may be neuroinvasive and/or indirectly affects the CNS and PNSA well-written review with useful information for cliniciansRomoli et al., 2020 \[[@CR100]\]To identify cases of confirmed nervous system invasion or post-infectious manifestationApril 24, 2020Twenty-seven studies: 14 case reports, 5 series, 2 case--control, 2 cross-sectional, 2 prospective, and 2 retrospective studiesCVA, GBS, encephalopathy meningitis, encephalitis, smell and taste changesMore precise and larger clinical studies are required with follow up. Suggested a reporting system for future research in the topicProvides useful guidance for future research and reporting*GBS* Guillain--Barré syndrome, *CNS* central nervous system, *CVA* cerebrovascular disease, *PNS* peripheral nervous system, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2

Conclusions {#Sec12}
===========

Neurological manifestations of COVID-19 are not rare, especially large vessel stroke, Guillain--Barre syndrome, and meningoencephalitis. They could be related to the direct cytopathic effect of the virus, the inflammatory response, hypercoagulable state, or complications of treatment and ICU stay. Moving forward, further studies are needed to clarify the prevalence of the neurological complications of COVID-19, investigate their biological background, and test treatment options. Physicians should be cautious not to overlook other neurological diagnoses that can mimic COVID-19 during the pandemic.
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